Bristol Myers Squibb reports two Phase 3 wins for Bristol Myers Squibb stock

Published on 10/15/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock costs EUR 53.66 on October 15, 2026, against a USD 121.1 billion market value. Q2 revenue rose 5.7 percent.

Pipeline updates and quarterly results

Admilparant met its primary endpoint at the 60 mg dose on October 12, 2026.
Second-quarter revenue reached USD 12.97 billion and rose 5.7 percent year over year.
Bristol Myers Squibb stock trades at EUR 53.66 at 10:38 a.m. CEST at Lang & Schwarz on October 15, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) was trading at EUR 53.66 at Lang & Schwarz on October 15, 2026, at 10:38 a.m. CEST. The company reported two Phase 3 developments on October 12, 2026, with one lung-disease trial meeting its primary endpoint at the 60 mg dose and a cancer trial showing improved progression-free survival.

According to StockTitan, Bristol Myers Squibb said the ALOFT-IPF trial produced a statistically significant improvement in forced vital capacity at Week 52 for admilparant 60 mg twice daily. The 120 mg dose slowed lung-function decline but did not reach statistical significance.

Two trials strengthen the pipeline

The ACTION-1 trial supplied the second clinical signal. StockTitan reported on October 12, 2026, that RYZ101 met its primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival. Bristol Myers Squibb said detailed results would be presented at a future medical meeting.

The chronology shows how quickly the pipeline story developed. On October 8, 2026, ZENBEXUS reduced the risk of progression or death by 51 percent in a Phase 3 multiple-myeloma study, according to MarketBeat. On October 12, the ALOFT-IPF and ACTION-1 trials delivered the latest updates.

What does the pipeline mean for growth?

The clinical progress matters because Bristol Myers Squibb entered the period with substantial commercial scale. The company reported USD 12.97 billion of second-quarter revenue, up 5.7 percent from the same quarter a year earlier, while adjusted earnings per share of USD 2.04 exceeded the USD 1.60 consensus, according to MarketBeat. The lower-dose ALOFT result still leaves investors assessing efficacy and dosing flexibility before regulatory submissions.